← All trials
NCT06899477
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Apr 30, 2033
- Completion date
- Apr 30, 2035
- First posted
- Mar 28, 2025
- Last posted
- Mar 28, 2025
- Enrollment
- 714
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humboldt UniversityLead sponsor
- Humboldt UniversitySponsor investigator
- Institut für Klinische Krebsforschung IKF GmbHCollaborator
- Humboldt UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.